[Monoclonal antibodies: also for dermatologists!]

Area of Science:

• Immunology
• Dermatology

Background:

• Therapeutic monoclonal antibodies are increasingly used for chronic inflammatory skin diseases like psoriasis, chronic spontaneous urticaria, and atopic dermatitis.
• These conditions previously shared treatment approaches, but targeted therapies offer new management strategies.

Purpose of the Study:

• To review the use of specific monoclonal antibodies (dupilumab, omalizumab, lanadelumab) in dermatology.
• To highlight the importance of understanding inflammatory pathways for targeted treatment development.
• To discuss the cost-benefit analysis of these advanced therapies.

Main Methods:

• Review of current literature on monoclonal antibody therapies.
• Analysis of treatment mechanisms and clinical applications.
• Discussion of economic and clinical considerations.

Main Results:

• Dupilumab, omalizumab, and lanadelumab represent key advancements in managing these chronic skin conditions.
• Understanding specific inflammatory pathways enables targeted therapeutic development.
• The efficacy of these treatments must be weighed against their significant cost.

Conclusions:

• Monoclonal antibodies offer targeted and effective treatment options for psoriasis, chronic spontaneous urticaria, and atopic dermatitis.
• Treatment decisions should incorporate disease severity, first-line treatment optimization, and long-term benefit-risk assessment.
• Further economic evaluation is necessary to contextualize the high cost of these advanced therapies.